risperidone has been researched along with Dementia, Vascular in 29 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Dementia, Vascular: An imprecise term referring to dementia associated with CEREBROVASCULAR DISORDERS, including CEREBRAL INFARCTION (single or multiple), and conditions associated with chronic BRAIN ISCHEMIA. Diffuse, cortical, and subcortical subtypes have been described. (From Gerontol Geriatr 1998 Feb;31(1):36-44)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the effects of galantamine and risperidone on agitation in patients with dementia." | 9.19 | Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. ( Aarsland, D; Auestad, B; Bloniecki, V; Freund-Levi, Y; Lärksäter, M; Tysen Bäckström, AC, 2014) |
| "To examine the effect of risperidone on specific behavioral and psychological symptoms of dementia (BPSD)." | 9.11 | Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. ( Brodaty, H; Davidson, M; De Deyn, PP; Greenspan, A; Katz, IR; Rabinowitz, J, 2004) |
| "This randomized, double-blind, placebo-controlled trial examined the efficacy and safety of risperidone in the treatment of aggression, agitation, and psychosis in elderly nursing-home patients with dementia." | 9.10 | A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. ( Ames, D; Brodaty, H; Clarnette, R; Grossman, F; Kirwan, J; Lee, E; Lyons, B; Snowdon, J; Woodward, M, 2003) |
| "We report the findings from the first large, double-blind, placebo-controlled study conducted to evaluate the efficacy and safety of risperidone in the treatment of psychotic and behavioral symptoms in institutionalized elderly patients with dementia." | 9.09 | Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. ( Brecher, M; Clyde, C; Jeste, DV; Katz, IR; Mintzer, JE; Napolitano, J, 1999) |
| "The authors studied the incidence of tardive dyskinesia in elderly institutionalized patients with dementia being treated with risperidone." | 9.09 | Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. ( Jeste, DV; Kane, JM; Martinez, RA; Napolitano, J; Okamoto, A, 2000) |
| "To examine the effects of galantamine and risperidone on agitation in patients with dementia." | 5.19 | Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. ( Aarsland, D; Auestad, B; Bloniecki, V; Freund-Levi, Y; Lärksäter, M; Tysen Bäckström, AC, 2014) |
| "To examine the effect of risperidone on specific behavioral and psychological symptoms of dementia (BPSD)." | 5.11 | Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. ( Brodaty, H; Davidson, M; De Deyn, PP; Greenspan, A; Katz, IR; Rabinowitz, J, 2004) |
| "This randomized, double-blind, placebo-controlled trial examined the efficacy and safety of risperidone in the treatment of aggression, agitation, and psychosis in elderly nursing-home patients with dementia." | 5.10 | A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. ( Ames, D; Brodaty, H; Clarnette, R; Grossman, F; Kirwan, J; Lee, E; Lyons, B; Snowdon, J; Woodward, M, 2003) |
| "We report the findings from the first large, double-blind, placebo-controlled study conducted to evaluate the efficacy and safety of risperidone in the treatment of psychotic and behavioral symptoms in institutionalized elderly patients with dementia." | 5.09 | Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. ( Brecher, M; Clyde, C; Jeste, DV; Katz, IR; Mintzer, JE; Napolitano, J, 1999) |
| "The authors studied the incidence of tardive dyskinesia in elderly institutionalized patients with dementia being treated with risperidone." | 5.09 | Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. ( Jeste, DV; Kane, JM; Martinez, RA; Napolitano, J; Okamoto, A, 2000) |
| "Haloperidol-treated patients showed a worsening on Simpson-Angus scale while there was no significant change in this measure in risperidone-treated patients." | 2.70 | A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. ( Chan, WC; Chiu, HF; Choy, CN; Lam, LC; Leung, VP; Li, SW, 2001) |
| "However, patients with vascular dementia had an increased risk in hospitalization for a CVE." | 1.34 | Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. ( Barnett, MJ; Perry, PJ; Wehring, H, 2007) |
| "The authors report 2 cases, in Alzheimer's disease and vascular dementia, in which erotomania emerged in the early stage of the underlying disorder." | 1.32 | Erotomania variants in dementia. ( Brüne, M; Schröder, SG, 2003) |
| "Risperidone was highly effective and well tolerated in the treatment of behavioural disturbances in dementia under routine conditions of general practice." | 1.32 | [Treatment of behavioral disorders in dementia with risperidone in psychogeriatric out-patients]. ( Delius-Stute, H; Kurz, A; Rettig, K; Schwalen, S, 2003) |
| "Haloperidol was abruptly shifted to risperidone 0." | 1.31 | Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects. ( Chang, WH; Chang, YC; Chiu, CC; Huang, MC; Lane, HY; Su, MH, 2002) |
| " In this case, NMS seemed to be induced by bacterial pneumonia after long term administration of LPZ 5 mg per day." | 1.30 | [A study of neuroleptic malignant syndrome in the presenium and senium]. ( Honma, H; Koyama, T; Matsubara, S; Suzuki, I; Watanabe, N, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.34) | 18.2507 |
| 2000's | 24 (82.76) | 29.6817 |
| 2010's | 1 (3.45) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Mühlbauer, V | 1 |
| Möhler, R | 1 |
| Dichter, MN | 1 |
| Zuidema, SU | 1 |
| Köpke, S | 1 |
| Luijendijk, HJ | 1 |
| Freund-Levi, Y | 1 |
| Bloniecki, V | 1 |
| Auestad, B | 1 |
| Tysen Bäckström, AC | 1 |
| Lärksäter, M | 1 |
| Aarsland, D | 1 |
| Forlenza, OV | 1 |
| Cretaz, E | 1 |
| Diniz, BS | 1 |
| Friedman, JH | 1 |
| Fernandez, HH | 1 |
| Shamreĭ, VK | 1 |
| Kolchev, AI | 1 |
| Dobrovol'skaia, NV | 1 |
| Brodaty, H | 6 |
| Ames, D | 2 |
| Snowdon, J | 3 |
| Woodward, M | 2 |
| Kirwan, J | 2 |
| Clarnette, R | 2 |
| Lee, E | 2 |
| Lyons, B | 2 |
| Grossman, F | 1 |
| Brüne, M | 1 |
| Schröder, SG | 1 |
| Lu, ML | 1 |
| Shen, WW | 1 |
| Sluys, M | 1 |
| Güzelcan, Y | 1 |
| Casteelen, G | 1 |
| de Haan, L | 1 |
| Kurz, A | 1 |
| Delius-Stute, H | 1 |
| Rettig, K | 1 |
| Schwalen, S | 1 |
| Rabinowitz, J | 2 |
| Katz, IR | 3 |
| De Deyn, PP | 3 |
| Greenspan, A | 3 |
| Davidson, M | 2 |
| Kleinman, L | 1 |
| Frank, L | 1 |
| Ciesla, G | 1 |
| Rupnow, M | 1 |
| Lacomblez, L | 1 |
| Burns, A | 1 |
| Deberdt, WG | 1 |
| Dysken, MW | 1 |
| Rappaport, SA | 1 |
| Feldman, PD | 1 |
| Young, CA | 1 |
| Hay, DP | 1 |
| Lehman, DL | 1 |
| Dossenbach, M | 1 |
| Degenhardt, EK | 1 |
| Breier, A | 1 |
| Suh, GH | 1 |
| Shah, A | 1 |
| Katz, I | 1 |
| Cohen-Mansfield, J | 1 |
| Formiga, F | 1 |
| Fort, I | 1 |
| Pérez-Castejón, JM | 1 |
| Ruiz, D | 1 |
| Duaso, E | 1 |
| Riu, S | 1 |
| Madhusoodanan, S | 1 |
| Bogunovic, O | 1 |
| Barnett, MJ | 1 |
| Wehring, H | 1 |
| Perry, PJ | 1 |
| Jeanblanc, W | 1 |
| Davis, YB | 1 |
| Suzuki, I | 1 |
| Honma, H | 1 |
| Watanabe, N | 1 |
| Matsubara, S | 1 |
| Koyama, T | 1 |
| Jeste, DV | 2 |
| Mintzer, JE | 1 |
| Clyde, C | 1 |
| Napolitano, J | 2 |
| Brecher, M | 1 |
| Okamoto, A | 1 |
| Kane, JM | 1 |
| Martinez, RA | 1 |
| Laks, J | 1 |
| Engelhardt, E | 1 |
| Marinho, V | 1 |
| Rozenthal, M | 1 |
| Souza, FC | 1 |
| Bacaltchuk, J | 1 |
| Stoppe, A | 1 |
| Ferreira, RC | 1 |
| Bottino, C | 1 |
| Scalco, M | 1 |
| Chan, WC | 1 |
| Lam, LC | 1 |
| Choy, CN | 1 |
| Leung, VP | 1 |
| Li, SW | 1 |
| Chiu, HF | 1 |
| Lane, HY | 1 |
| Chang, YC | 1 |
| Su, MH | 1 |
| Chiu, CC | 1 |
| Huang, MC | 1 |
| Chang, WH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00036114] | Phase 3 | 0 participants | Interventional | 2000-03-31 | Completed | ||
| A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease[NCT02035553] | Phase 2 | 181 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Risperidone in the Treatment of Behavioural and Psychological Signs and Symptoms in Dementia (BPSSD): a Multicentre, Double-blind, Placebo-controlled Parallel-group Trial[NCT00249158] | Phase 3 | 344 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia[NCT00253123] | Phase 3 | 626 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from Baseline to Day 43 in the Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) psychosis score (Delusions [Domain A]+Hallucinations [Domain B]) in the Full Analysis Set (FAS). The NPI-NH is a questionnaire that quantifies behavioral changes in dementia in nursing home patients and evaluates 12 behavioral domains. For each of the 12 behavioral domains the Frequency (scale:1=occasionally to 4=very frequently) is multiplied by the Severity (scale:1=Mild to 3=Severe) to obtain a domain score (frequency x severity), The NPI-NH Psychosis Subscale consists of the two domains of Delusions and Hallucinations, calculated by adding the Individual domain scores, to yield a possible total score of 0 to 24. Lower scores correspond to less severity. A negative change score from baseline indicates improvement. (NCT02035553)
Timeframe: Day 43
| Intervention | Score on the NPI-NH scale (Least Squares Mean) |
|---|---|
| Placebo | -1.93 |
| Pimavanserin 40 mg | -3.76 |
4 reviews available for risperidone and Dementia, Vascular
| Article | Year |
|---|---|
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Humans; Psychotic Disorders; Randomized | 2021 |
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Humans; Psychotic Disorders; Randomized | 2021 |
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Humans; Psychotic Disorders; Randomized | 2021 |
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Humans; Psychotic Disorders; Randomized | 2021 |
[The use of antipsychotics in patients with dementia].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cerebrovascular Disorders; Dementia; Dementia, | 2008 |
Atypical antipsychotics in Parkinson-sensitive populations.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia, Vascular; Dibenzothia | 2002 |
Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dementia, Vascular; Double-Bl | 2005 |
10 trials available for risperidone and Dementia, Vascular
| Article | Year |
|---|---|
Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia; Dementia, Vascular; Fema | 2014 |
A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dementia, Vascula | 2003 |
Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Dementia; Dementia, Vascular; Female; Hum | 2004 |
Psychometric performance of an assessment scale for strain in nursing care: the M-NCAS.
Topics: Aged; Aggression; Alzheimer Disease; Australia; Dementia, Vascular; Double-Blind Method; Female; Hum | 2004 |
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaze | 2005 |
Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Double-Blind M | 2005 |
Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases | 1999 |
Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia; Dementia, Vascular; Dose | 2000 |
Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly.
Topics: Administration, Oral; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dementi | 2001 |
A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia, Vascular; Double-Blind Method; Female; Haloper | 2001 |
15 other studies available for risperidone and Dementia, Vascular
| Article | Year |
|---|---|
[Effectiveness of rispolept in mental disorders in patients with Alzheimer and vascular types of dementia].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Female; Humans; Male; Middle Aged | 2002 |
Erotomania variants in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bipolar Disorder; Delusions; Dementia, Vascular; Dopamin | 2003 |
Sleep-related eating disorder induced by risperidone.
Topics: Aged; Antipsychotic Agents; Dementia, Vascular; Dose-Response Relationship, Drug; Humans; Hyperphagi | 2004 |
Risperidone-induced leucopenia and neutropenia: a case report.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delusions; Dementia, Vascular; Hallucinations; Halope | 2004 |
[Treatment of behavioral disorders in dementia with risperidone in psychogeriatric out-patients].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Antipsychotic Agents; Butyrophenones; C | 2003 |
[Cerebral infarct and atypical antipsychotic agents].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cerebral Infarction; Dementia, Vascu | 2004 |
Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Confidence Intervals; Dementia, Va | 2005 |
Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Cross-Sectional Studie | 2005 |
Psychosis of Alzheimer disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cause of Death; Controlled Clinical | 2006 |
[Risperidone and cerebrovascular adverse effects in elderly patients with dementia].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cerebrovascular Disorders; Cholinesterase Inhibitors; | 2006 |
The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzodiazepines; Comorbidity; Dementia, Vascular; Dose-R | 2007 |
Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Databases, Factual; Dementia, Vascul | 2007 |
Risperidone for treating dementia-associated aggression.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Dementia; Dementia, Vascular; Female; Humans | 1995 |
[A study of neuroleptic malignant syndrome in the presenium and senium].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Female; Haloperidol; Humans; Male | 1998 |
Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects.
Topics: Activities of Daily Living; Affect; Aged; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascula | 2002 |